|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | BRC Operations Pty. Ltd. |
|---|---|
| Information provided by (Responsible Party): | BRC Operations Pty. Ltd. |
| ClinicalTrials.gov Identifier: | NCT00693849 |
Purpose
The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine, Sertraline) in patients diagnosed with major depressive disorder. This study is focused on outcomes which may impact on how "personalised medicine" is implemented in depression.
| Condition | Intervention | Phase |
|---|---|---|
|
Major Depressive Disorder |
Drug: Escitalopram Drug: Sertraline Drug: Venlafaxine XR |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Health Services Research |
| Official Title: | International Study to Predict Optimised Treatment - in Depression |
| Estimated Enrollment: | 2688 |
| Study Start Date: | September 2008 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: A
Escitalopram
|
Drug: Escitalopram
10 mg/day as a single dose, increased to max 20 mg/day
Other Name: Lexapro
|
|
Active Comparator: B
Sertraline
|
Drug: Sertraline
50 mg/day as a single dose, increased to max of 200 mg/day
Other Name: Zoloft
|
|
Active Comparator: C
Venlafaxine
|
Drug: Venlafaxine XR
75 mg/day given once daily; increased to 150-225 mg/day
Other Name: Effexor
|
|
No Intervention: D
Healthy matched controls
|
This is an open-label, randomised (effectiveness) study (ie. comparison of active treatments) to identify genetic markers, brain function, brain structure, and psychological and cognitive indicators (or a combination of markers) in MDD subjects versus healthy controls. Approximately 2,016 subjects with major depressive disorder (MDD) across multiple international sites (USA, Canada, UK, South Africa, New Zealand, The Netherlands and Australia) will be randomised to one of three approved and effective treatment arms:
Treatment A Escitalopram. Treatment B Sertraline. Treatment C Venlafaxine XR.
A group of matched healthy controls (n = 672) will also be enrolled.
Subjects will be asked to attend the testing facility on two separate occasions; for Pre-treatment (Pre-Tx) and at 8 weeks post initiation of treatment. The assessments/procedures at Pre-Tx and Week 8 include: Baseline a clinical work-up, blood collection for genetic analyses, cognitive testing and electrical brain functioning (EEG/ERP). Structural and functional data MRI data will be collected in ten percent (10%) of participants.
On Day 4 and Weeks 2, 4, 6, 12, 16, 24 and 52 Subjects will be contacted by phone and asked to complete 2 questionnaires via the internet.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |
| Shanti Clinical Trials | Active, not recruiting |
| Colton, California, United States, 92324 | |
| A.D.D. Treatment Center | Recruiting |
| Mission Viejo, California, United States, 92691 | |
| Contact: Jeffrey Wilson, PhD 949-272-3870 jwilson@addtreatmentcenters.org | |
| Principal Investigator: Jeffrey Wilson, Ph.D. | |
| Stanford University | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Maureen Chang 650-725-4620 mhchang@stanford.edu | |
| Principal Investigator: Charles Debattista, MD | |
| Center for Healing the Human Spirit | Recruiting |
| Tarzana, California, United States, 91356 | |
| Contact: Barbara A. Cohen, PhD 818-343-1331 drbarbara@healingthehumanspirit.com | |
| Principal Investigator: Barbara A. Cohen, PhD | |
| United States, Missouri | |
| University of Missouri - St. Louis | Completed |
| St. Louis, Missouri, United States, 63121 | |
| United States, New Jersey | |
| Brain Resource Center | Completed |
| Englewood Cliffs, New Jersey, United States, 07632 | |
| United States, New York | |
| Brain Resource Center | Completed |
| New York, New York, United States, 10023 | |
| Weill Cornell Medical Center | Recruiting |
| White Plains, New York, United States, 10605 | |
| Contact: Eric Wood 914-997-5463 erw2005@med.cornell.edu | |
| Principal Investigator: XiaoLei Yu Baran, MD | |
| United States, North Carolina | |
| Skyland Behavioral Health Associates , P.A. | Completed |
| Ashville, North Carolina, United States, 28801 | |
| United States, Ohio | |
| Ohio State University | Recruiting |
| Columbus, Ohio, United States, 43210 | |
| Contact: Meriden Peters 614-293-7109 meriden.peters@osumc.edu | |
| Principal Investigator: Radu Saveanu, MD | |
| Principal Investigator: Subhdeep Virk, MD | |
| United States, Rhode Island | |
| NeuroDevelopment Center | Completed |
| Providence, Rhode Island, United States, 02903 | |
| Australia, New South Wales | |
| Brain Dynamic Centre | Recruiting |
| Westmead, New South Wales, Australia, 2145 | |
| Contact: Christine Song, MD, PhD +61 (02) 9845 6844 Yun.song@sydney.edu.au | |
| Principal Investigator: Anthony Harris, MD | |
| Principal Investigator: Tim Usherwood, MD | |
| Australia, South Australia | |
| Flinders University | Completed |
| Adelaide, South Australia, Australia, 5042 | |
| Australia, Victoria | |
| Delmont Private Hospital | Recruiting |
| Glen Iris, Victoria, Australia, 3146 | |
| Contact: Linda Nolasco +61 (03) 9076 8045 L.Nolasco@alfred.org | |
| Principal Investigator: Jayashri Kulkarni, Prof | |
| Swinburne University | Recruiting |
| Melbourne, Victoria, Australia, 3122 | |
| Contact: Amy Gibbs +61 (03) 9214 8229 agibbs@groupwise.swin.edu.au | |
| Principal Investigator: Con Stough, Ph.D. | |
| The Alfred Hospital | Recruiting |
| Melbourne, Victoria, Australia, 3181 | |
| Contact: Antonia Jakobson +61 (03) 9076 6589 A.Jakobson@alfred.org.au | |
| Principal Investigator: Paul Fitzgerald, MD | |
| Principal Investigator: Jayashri Kulkarni, Prof | |
| Netherlands | |
| Brainclinics Diagnostics B.V. | Recruiting |
| Nijmegen, Gelderland, Netherlands, 6524 AD | |
| Contact: Niels Veth, PhD +31 (0)24 750 3509 cpmveth@brainclinics.com | |
| Principal Investigator: Martijn Arns, PhD | |
| New Zealand | |
| University of Auckland | Recruiting |
| Auckland, New Zealand, 1142 | |
| Contact: Mirjana Stojkovic +64 (0)9 923 3774 m.stojkovic@auckland.ac.nz | |
| Principal Investigator: Bruce Russell, PhD | |
| South Africa | |
| Brain Health Lab | Completed |
| Johannesburg, Guatang, South Africa, 2191 | |
| Principal Investigator: | Anthony Harris, MD | Brain Dynamics Centre |
| Principal Investigator: | Barbara A. Cohen, PhD | Center for Healing the Human Spirit |
| Principal Investigator: | Bruce Russell, PhD | University of Auckland, New Zealand |
| Principal Investigator: | Charles Debattista, MD | Stanford University |
| Principal Investigator: | Con Stough, PhD | Swinburne University |
| Principal Investigator: | Elizabeth Wallis, PhD | Brain Health Lab |
| Principal Investigator: | Harbans Multani, MD | Shanti Clinical Trials |
| Principal Investigator: | Jayashri Kulkarni, Prof | The Alfred and Delmont Private Hospital |
| Principal Investigator: | Jeffrey Wilson, PhD | A.D.D. Treatment Center |
| Principal Investigator: | Kamran Fallahpour, PhD | Brain Resource Center |
| Principal Investigator: | Larry Hirshberg, PhD | NeuroDevelopment Center |
| Principal Investigator: | Martijn Arns, PhD | Brainclinics Diagnostics B.V. |
| Principal Investigator: | Mona Ismail, MD | Brain Resource Center |
| Principal Investigator: | Paul Fitzgerald, PhD | The Alfred Hospital |
| Principal Investigator: | Richard Clark, PhD | Flinders University |
| Principal Investigator: | Roger deBeus, PhD | Skyland Behavioral Health Associates |
| Principal Investigator: | Steven Bruce, PhD | University of Missouri, St. Louis |
| Principal Investigator: | Subhdeep Virk, MD | Ohio State University |
| Principal Investigator: | Tim Usherwood, MD | Brain Dynamics Centre |
More Information
| Responsible Party: | BRC Operations Pty. Ltd. |
| ClinicalTrials.gov Identifier: | NCT00693849 History of Changes |
| Other Study ID Numbers: | iSPOT-D |
| Study First Received: | June 6, 2008 |
| Last Updated: | January 5, 2012 |
| Health Authority: | United States: Institutional Review Board; Australia: National Health and Medical Research Council; Netherlands: The Central Committee on Research Involving Human Subjects (CCMO); South Africa: Human Research Ethics Committee |
|
depression CNS iSPOT MDD |
|
Depression Depressive Disorder Depressive Disorder, Major Behavioral Symptoms Mood Disorders Mental Disorders Dexetimide Citalopram Sertraline Venlafaxine Antiparkinson Agents Anti-Dyskinesia Agents Central Nervous System Agents Therapeutic Uses Pharmacologic Actions |
Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Serotonin Agents |